

**U.S. PRODUCERS' QUESTIONNAIRE**

**GLYCINE FROM CHINA**

**This questionnaire must be received by the Commission by no later than April 27, 2011**

*See page 4 of the Instruction Booklet for filing instructions.*

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its review of the antidumping duty order concerning glycine from China (Inv. No. 731-TA-718 (Third Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. **This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).**

Name of firm _____
Address _____
City _____ State _____ Zip Code _____
World Wide Web address _____
Has your firm produced <b>glycine</b> (as defined in the instruction booklet) at any time since January 1, 2005?
<input type="checkbox"/> <b>NO</b> (Sign the certification below and promptly return only this page of the questionnaire to the Commission)
<input type="checkbox"/> <b>YES</b> (Read the instruction booklet carefully, complete all parts of the questionnaire, and return the entire questionnaire to the Commission so as to be received by the date indicated above)

**CERTIFICATION**

*I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge and belief and understand that the information submitted is subject to audit and verification by the Commission.*

*By means of this certification I also grant consent for the Commission, and its employees and contract personnel, to use the information provided in this questionnaire and throughout this review in any other import-injury proceedings or reviews conducted by the Commission on the same or similar merchandise.*

*I acknowledge that information submitted in this questionnaire response and throughout this review may be used by the Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or maintaining the records of this review or related proceedings for which this information is submitted, or in internal audits and proceedings relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all contract personnel will sign non-disclosure agreements.*

_____ <i>Name of Authorized Official</i>	_____ <i>Title of Authorized Official</i>	_____ <i>Date</i>
_____ <i>Signature</i>	_____ <i>Phone: ( )</i>	_____ <i>E-mail address</i>
	_____ <i>Fax ( )</i>	

**PART I.—GENERAL INFORMATION**

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

I-1a. **OMB statistics.**--Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

\_\_\_\_\_hours \_\_\_\_\_dollars

I-1b. **OMB feedback.**--We are interested in any comments you may have for improving this questionnaire in general or the clarity of specific questions. Please attach such comments to your response or send them to the above address.

I-2. **Establishments covered.**--Provide the name and address of establishment(s) covered by this questionnaire (see page 3 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol.

---

---

I-3. **Position regarding continuation of order.**--Do you support or oppose continuation of the antidumping duty order currently in place for glycine from China?

**China**  Support  Oppose  Take no position

---

---

**PART I.--GENERAL INFORMATION--Continued**

I-4. **Ownership.**--Is your firm owned, in whole or in part, by any other firm?

No       Yes--List the following information.

<u>Firm name</u>	<u>Address</u>	<u>Extent of ownership</u>
_____	_____	_____
_____	_____	_____
_____	_____	_____

I-5. **Related SUBJECT importers/exporters.**--Does your firm have any related firms, either domestic or foreign, that are engaged in **importing glycine from China** into the United States or that are engaged in exporting glycine from China to the United States?

No       Yes--List the following information.

<u>Firm name</u>	<u>Address</u>	<u>Affiliation</u>
_____	_____	_____
_____	_____	_____
_____	_____	_____

I-6. **Related NONSUBJECT importers/exporters.**--Does your firm have any related firms, either domestic or foreign, that are engaged in **importing glycine from countries other than China** into the United States or that are engaged in exporting glycine from countries other than China to the United States?

No       Yes--List the following information.

<u>Firm name and country</u>	<u>Address</u>	<u>Affiliation</u>
_____	_____	_____
_____	_____	_____
_____	_____	_____

**PART I.--GENERAL INFORMATION--Continued**

I-7. **Related producers.**--Does your firm have any related firms, either domestic or foreign, that are engaged in the production of glycine?

No             Yes--List the following information.

<u>Firm name</u>	<u>Address</u>	<u>Affiliation</u>
_____	_____	_____
_____	_____	_____
_____	_____	_____

I-8. **Business plan.**--In Parts II and IV of this questionnaire we request a copy of your company's business plan. Does your company or any related firm have a business plan or any internal documents that describe, discuss, or analyze expected market conditions for glycine?

No             Yes--Please provide the requested documents. If you are not providing the requested documents, please explain why not.

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

**PART II.—TRADE AND RELATED INFORMATION**

Further information on this part of the questionnaire can be obtained from **Stefania Pozzi Porter (202-205-3177, [Stefania.PozziPorter@usitc.gov](mailto:Stefania.PozziPorter@usitc.gov))**. **Supply all data requested on a calendar-year basis.**

II-1. Please identify the individual to be contacted regarding the confidential information requested in part II.

Name and title: \_\_\_\_\_

Please indicate the manner by which Commission staff may contact the individual responsible for part II with questions regarding the submitted confidential information.

E-mail: \_\_\_\_\_ Telephone: (\_\_\_\_) \_\_\_\_\_

Fax: (\_\_\_\_) \_\_\_\_\_

II-2. **Changes in operations.**--Please indicate whether your firm has experienced any of the following changes in relation to the production of glycine since January 1, 2005.

- | <i>(check as many as appropriate)</i>  | <i>(please describe)</i> |
|--|--------------------------|
| <input type="checkbox"/> plant openings .....                                    | _____<br>_____           |
| <input type="checkbox"/> plant closings.....                                     | _____<br>_____           |
| <input type="checkbox"/> relocations .....                                       | _____<br>_____           |
| <input type="checkbox"/> expansions .....  | _____<br>_____           |
| <input type="checkbox"/> acquisitions.....                                       | _____<br>_____           |
| <input type="checkbox"/> consolidations.....                                     | _____<br>_____           |
| <input type="checkbox"/> prolonged shutdowns or<br>production curtailments ..... | _____<br>_____           |
| <input type="checkbox"/> revised labor agreements.....                           | _____<br>_____           |
| <input type="checkbox"/> other ( <i>e.g.</i> , technology) .....                 | _____<br>_____           |

**PART II.—TRADE AND RELATED INFORMATION--Continued**

II-3. **Anticipated changes in operations.**--Does your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of glycine in the future?

- No                       Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation that address this issue. **Include in your response a specific projection of your firm's capacity to produce glycine (in 1,000 pounds) for 2011 and 2012.**

---

---

---

II-4. **Anticipated changes in operations in the event the order is revoked.**--Would your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of glycine in the future if the antidumping duty order on glycine from China were to be revoked?

- No                       Yes--Supply details as to the time, nature, and significance of such changes, and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation that address this issue. **Include in your response a specific projection of your firm's capacity to produce glycine (in 1,000 pounds) for 2011 and 2012.**

---

---

---

**PART II.—TRADE AND RELATED INFORMATION--Continued**

II-5. **Same equipment, machinery, and workers.**--Has your firm since 2005 produced, or does your firm anticipate producing in the future, other products on the same equipment and machinery used in the production of glycine and/or using the same production and related workers employed to produce glycine?

- No                       Yes--List the following information and report your firm's combined production capacity and production of these products and glycine in the periods indicated.

<b><u>Product</u></b>	<b><u>Period</u></b>	<b><u>Basis for allocation of capacity and employment data (indicate if different)</u></b>
_____	_____	_____
_____	_____	_____
_____	_____	_____

<i>(Quantity in 1,000 pounds)</i>						
<b>Item</b>	<b>2005</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>	<b>2010</b>
<b>Overall Production Capacity</b>						
<b>Production of:</b>						
Glycine						
Other product 1 _____						
Other product 2 _____						

II-6. **Constraints on production.**--Please describe the constraint(s) that set the limit(s) on your production capacity.

\_\_\_\_\_

\_\_\_\_\_

II-7. **Production shifting.**--Is your firm able to switch production between glycine and other products in response to a relative change in the price of glycine vis-a-vis the price of other products, using the same equipment and/or labor?

- No                       Yes--Please identify the other products, the approximate time and cost involved in switching, and the minimum relative price change required for your firm to switch production to or from glycine.

\_\_\_\_\_

\_\_\_\_\_

**PART II.—TRADE AND RELATED INFORMATION--Continued**

II-8. **Trade data.**--Report your firm's production capacity, production, shipments, inventories, and employment related to the production of glycine in your U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

Quantity (in 1,000 pounds) and value (in \$1,000)						
Item	Calendar year					
	2005	2006	2007	2008	2009	2010
<b>Average production capacity<sup>1</sup></b> (quantity) (A)						
<b>Beginning-of-period inventories</b> (quantity) (B)						
<b>Production</b> (quantity) (C)						
<b>U.S. shipments:</b>						
<b>Commercial shipments:</b>						
quantity (D)						
value (E)						
<b>Internal consumption:<sup>2</sup></b>						
quantity (F)						
value (G)						
<b>Transfers to related firms:<sup>2</sup></b>						
quantity (H)						
value (I)						
<b>Export shipments:<sup>3</sup></b>						
quantity (J)						
value (K)						
<b>End-of-period inventories</b> (quantity) (L)						
<b>Channels of distribution:</b>						
U.S. shipments to distributors (quantity) (M)						
U.S. shipments to end users (quantity) (N)						
<b>Employment data:</b>						
Average number of PRWs (number) (O)						
Hours worked by PRWs (1,000 hours) (P)						
Wages paid to PRWs (value) (Q)						
<p><sup>1</sup> The production capacity (see definitions in instruction booklet) reported is based on operating ____ hours per week, ____ weeks per year. Please describe the methodology used to calculate production capacity, and explain any changes in reported capacity (use additional pages as necessary).</p>						
<p><sup>2</sup> Internal consumption and transfers to related firms should be valued at fair market value. In the event that you use a different basis for valuing these transactions, please specify that basis (e.g., cost, cost plus, etc.) and provide value data using that basis for each of the periods noted above:</p>						
<p><sup>3</sup> Identify your principal export markets: _____</p>						



**PART II.—TRADE AND RELATED INFORMATION--Continued**

**II-9. Reconciliation of trade data.--**

(a) Please note that the quantities reported in question II-8 should reconcile as follows in each period (*i.e.*, in each column):

Reconciliation

$B + C - D - F - H - J = L$

Do these data reconcile?  Yes  No--Please explain \_\_\_\_\_

$D + F + H = M + N$

Do these data reconcile?  Yes  No--Please explain \_\_\_\_\_

(b) Please note that the quantities reported for end-of-period inventories should equal the beginning-of-period inventories reported in the subsequent calendar year (*i.e.*, line L of year 2005 should equal line B of year 2006). Do these data reconcile for each adjacent calendar year?

Yes.  No--Please explain.

\_\_\_\_\_  
\_\_\_\_\_

II-10. **Transfers to related firms.**--If you reported transfers to related firms in question II-8, please indicate the nature of the relationship between your firm and the related firms (*e.g.*, joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

II-11. Please indicate which production process your firm uses to produce glycine. (Check all that apply.)

**Hydrogen cyanide ("HCN") process** -- (This process uses formaldehyde, hydrogen cyanide, anhydrous ammonia, sodium hydroxide, and sulfuric acid as raw material inputs and/or catalysts to produce glycine. Sodium glycinate is a distinct intermediate product in this process.)

**Monochloroacetic acid ("MCA") process** -- (This process uses monochloroacetic acid, anhydrous ammonia, and hexamethyleneteramine (also known as hexamine) as raw material inputs and/or catalysts to produce glycine. Sodium glycinate is not an intermediate product in this production process.)

**Other**--Please describe: \_\_\_\_\_

**PART II.—TRADE AND RELATED INFORMATION--Continued**

II-12. **Purchases.**--Other than direct imports, has your firm otherwise purchased glycine since January 1, 2005? (See definitions in the instruction booklet.)

- No                       Yes-- Please indicate the reasons for your purchases (if your reasons differ by source, please elaborate) and report the quantity and value of such purchases below for the specified periods

Reasons: \_\_\_\_\_

<b>(Quantity in 1,000 pounds, value in \$1,000)</b>						
<b>Item</b>	<b>2005</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>	<b>2010</b>
PURCHASES FROM U.S. IMPORTERS <sup>1</sup> OF GLYCINE FROM.—						
China:						
<i>quantity</i>						
<i>value</i>						
All other countries:						
<i>quantity</i>						
<i>value</i>						
PURCHASES FROM DOMESTIC PRODUCERS: <sup>2</sup>						
<i>quantity</i>						
<i>value</i>						
PURCHASES FROM OTHER SOURCES:						
<i>quantity</i>						
<i>Value</i>						
<sup>1</sup> Please list the name of the importer(s) from which you purchased this product. If your suppliers differ by source, please identify the source for each listed supplier. _____ _____						
<sup>2</sup> Please list the name of the domestic producer(s) from which you purchased this product. _____ _____ _____						

II-13. **Toll production.**--Since January 1, 2005, has your firm been involved in a toll agreement (see definition in the instruction booklet) regarding the production of glycine?

- No                       Yes--Name firm(s): \_\_\_\_\_.

II-14. **FTZ.**--Does your firm produce glycine in a foreign trade zone (FTZ)?

- No                       Yes--Identify FTZ(s): \_\_\_\_\_.

**PART II.—TRADE AND RELATED INFORMATION--Continued**

II-15. **Direct imports.**--Since January 1, 2005, has your firm imported glycine?

- No
- Yes--**COMPLETE AND RETURN A U.S. IMPORTERS' QUESTIONNAIRE**

II-16. **Shipments by grade.**—Please report the quantity of your firm’s 2010 U.S shipments by grade of glycine (based on the actual quality of the glycine, not the market to which it is sold).

U.S. Shipments	
Product	Quantity (in 1,000 pounds)
Pharmaceutical grade	
USP grade	
Technical grade	
Other grade _____	

II-17. **Effect of order.**--Describe the significance of the existing antidumping duty order covering imports of glycine from China in terms of its effect on your firm’s production capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, and asset values. You may wish to compare your firm’s operations before and after the imposition of the order.

---



---



---

II-18. **Likely effect of revocation of order.**--Would your firm anticipate any changes in its production capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, or asset values relating to the production of glycine in the future if the antidumping duty order on glycine from China were to be revoked?

- No
- Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation for any trends or projections you may provide.

---



---



---



---

**PART III.—FINANCIAL INFORMATION**

Address questions on this part of the questionnaire to **Charles Yost (202-205-3432, Charles.Yost@usitc.gov)**.

III-1. Please identify the individual to be contacted regarding the confidential information requested in part III?

Name and title: \_\_\_\_\_

Please indicate the manner by which Commission staff may contact the individual responsible for part III with questions regarding the submitted confidential information.

E-mail: \_\_\_\_\_ Telephone: (\_\_\_\_) \_\_\_\_\_

Fax: (\_\_\_\_) \_\_\_\_\_

III-2. **General guidance:**--Financial data are requested on a product-line basis; the product is glycine, as defined in the instruction booklet. Inputs your firm receives from affiliates to produce glycine should be stated at cost (i.e., intra-firm profits eliminated, see question III-7) while transfers of glycine to related affiliates should be stated at fair market value. Please report all sales on an f.o.b. basis. Total sales in this section should equal total shipments plus exports in Part II, page 8 (trade data) of this questionnaire. PLEASE REPORT ALL FINANCIAL DATA ON A CALENDAR YEAR BASIS.

III-3. **Accounting system.**--Briefly describe your financial accounting system.

a) When does your fiscal year end (month and day)? \_\_\_\_\_ ;.

b) Describe the lowest level of operations (e.g., plant, division, company-wide) for which financial statements are prepared that include subject merchandise: \_\_\_\_\_

c) Does your firm prepare profit/loss statements for the subject merchandise:  
 Yes  No

d) How often did your firm (or parent company) prepare financial statements (including annual reports, 10Ks)? Please check relevant items below.

Audited,  unaudited,  annual reports,  10Ks,  10 Qs,  
 Monthly,  quarterly,  semi-annually,  annually

e) Accounting basis:  GAAP,  cash,  tax,  
or  other comprehensive (specify) \_\_\_\_\_

*Note: The Commission may request that your company submit copies of its financial statements, including internal profit-and-loss statements for the division or product group that includes glycine, as well as those statements and worksheets used to compile data for your firm's questionnaire response.*

III-4. **Cost accounting system.**--Briefly describe your cost accounting system (e.g., standard cost, job order cost, etc.).

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**PART III.—FINANCIAL INFORMATION--Continued**

III-5. **Allocation basis.**--Briefly describe your allocation basis, if any, for COGS, SG&A, and interest expense and other income and expenses.

---

---

III-6. **Other products.**--Please list any other products you produced in the facilities in which you produced glycine, and provide the share of net sales accounted for by these other products in your most recent fiscal year:

<u>Products</u>	<u>Share of sales</u>
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

III-7a. **Raw materials from related firms.**--Does your company receive inputs (raw materials, labor, energy, or any other services) used in the production of glycine from any related company?

Yes--Continue to question III-7b below.       No--Continue to question III-7c below.

III-7b. **Inputs from related firms.**--In the space provided below, identify the inputs used in the production of glycine that your firm receives from related parties whose financial statements are consolidated with the financial statements of your firm.

<u>Input</u>	<u>Related party</u>
_____	_____
_____	_____
_____	_____
_____	_____

**PART III.—FINANCIAL INFORMATION--Continued**

III-7c. **Inputs from related firms at cost.**--All intercompany profit on inputs purchased from related parties should be eliminated from the costs reported to the Commission in question III-10 (i.e., costs reported in question III-10, to the extent that they reflect inputs purchased from related parties, should only reflect the related party's cost and not include an associated profit component). Reasonable methods for determining and eliminating the associated profit on inputs purchased from related parties are acceptable.

Has your firm complied with the Commission's instructions regarding costs associated with inputs purchased from related parties?

Yes  No—Please contact **Charles Yost (202-205-3432, Charles.Yost@usitc.gov)**.

III-8. **Nonrecurring charges.**--For each annual period for which financial results are reported in question III-10, please indicate in the schedule below the specific nonrecurring charges, the particular expense/cost line items from question III-10 where the associated charges are included, a brief description of the charges, and the associated values (*in \$1,000*). Nonrecurring charges would include, but are not limited to, items such as asset write-offs and accelerated depreciation due to restructuring of the company's glycine operations.

Item	Calendar years ended--					
	2005	2006	2007	2008	2009	2010
Non-recurring charges: In the far left column please provide a brief description of each nonrecurring charge and indicate the particular expense/cost line item where the associated charge is included in question III-10.						
1.						
2.						
3.						
4.						
5.						
6.						
7.						

III-9. **By-products.**—For each annual period for which financial results are reported in question III-10, please deduct the net sales value on a f.o.b. basis of the by-products (salt cake or other, for example) that your firm recovered.

Please identify the by-products that your firm recovered and sold: \_\_\_\_\_.

Please report the net sales value f.o.b. that was deducted here for the six most recently completed calendar years:

2005: \$\_\_\_\_\_ 2006: \$\_\_\_\_\_ 2007: \$\_\_\_\_\_ 2008:\$\_\_\_\_\_ 2009: \$\_\_\_\_\_ 2010: \$\_\_\_\_\_

**PART III.—FINANCIAL INFORMATION--Continued**

III-10. **Operations on glycine.**--Report the revenue and related cost information requested below on the glycine operations of your U.S. establishment(s).<sup>1</sup> Do not report resales of purchased glycine. Note that internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost.<sup>2</sup> Provide data on a calendar year basis for the six most recently completed years in chronological order from left to right. **If your firm was involved in tolling operations (either as the toller or as the tollee) please contact Charles Yost (202-205-3432, Charles.Yost@usitc.gov) before completing this section of the questionnaire.**

Quantity (in 1,000 pounds) and value (in \$1,000)						
Item	2005	2006	2007	2008	2009	2010
<b>Net sales quantities:</b> <sup>3</sup>						
Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales quantities						
<b>Net sales values:</b> <sup>3</sup>						
Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales values						
<b>Cost of goods sold (COGS):</b> <sup>4</sup>						
Raw materials, net of by-products						
Direct labor						
Other factory costs						
Total COGS						
<b>Gross profit or (loss)</b>						
<b>Selling, general, and administrative (SG&amp;A) expenses:</b>						
Selling expenses						
General and administrative expenses						
Total SG&A expenses						
<b>Operating income (loss)</b>						
<b>Other income and expenses:</b>						
Interest expense						
All other expense items						
Continued Dumping and Subsidy Offset Act funds received <sup>5</sup>						
All other income items						
All other income or expenses, net						
<b>Net income or (loss) before income taxes</b>						
<b>Depreciation/amortization included above</b>						

<sup>1</sup> Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.  
<sup>2</sup> Please eliminate any profits or (losses) on inputs from related firms pursuant to question III-7.  
<sup>3</sup> Less discounts, returns, allowances, and prepaid freight. The total quantities and values should approximate the corresponding total shipment quantities and values reported in Part II of this questionnaire.  
<sup>4</sup> COGS should include costs associated with sales, internal consumption and transfers to related firms.  
<sup>5</sup> Please report funds received under this act in the period(s) in which they were received. Do not report these funds as an offset to operating expenses.

**PART III.—FINANCIAL INFORMATION--Continued**

III-11. **Asset values.**--Report the total assets associated with the production, warehousing, and sale of glycine. If your firm does not maintain some or all of the specific asset data in the normal course of business, please estimate it based upon some rational method (such as production, sales, or costs) that is consistent with your cost allocations in the previous question. Your finished goods inventory value should reconcile with the inventory quantity data reported in Part II. Provide data as of the end of your six most recently completed fiscal years in chronological order from left to right.

Item	Value (in \$1,000)					
	2005	2006	2007	2008	2009	2010
<b>ASSETS</b> associated with the production, warehousing, and sale of product:						
<b>1. Current assets:</b>						
A. Cash and equivalents						
B. Accounts receivable, net						
C. Finished goods inventories						
D. All other (describe:     )						
E. Total current assets (lines 1.A. through 1.D.)						
<b>2. Property, plant, and equipment</b>						
A. Original cost of property, plant, and equipment						
B. Less: Accumulated depreciation						
C. Equals: Book value of property, plant, and equipment						
<b>3. Other (describe:     )</b>						
<b>4. Total assets (lines 1.E., 2.C., and 3)</b>						

III-12. **Capital expenditures and research and development expenses.**--Report your firm's capital expenditures and research and development expenses on glycine. Provide data on a calendar year basis for the six most recently completed years in chronological order from left to right.

Item	Value (in \$1,000)					
	Calendar year					
	2005	2006	2007	2008	2009	2010
Capital expenditures						
Research and development expenses						



**PART IV.--PRICING AND MARKET FACTORS**

Further information on this part of the questionnaire can be obtained from **Aimee Larsen (202-205-3179, Aimee.Larsen@usitc.gov)**.

IV-1. Please identify the individual to be contacted regarding the confidential information requested in part IV?

Name and title: \_\_\_\_\_

Please indicate the manner by which Commission staff may contact the individual responsible for part IV with questions regarding the submitted confidential information.

E-mail: \_\_\_\_\_ Telephone: ( ) \_\_\_\_\_

Fax: ( ) \_\_\_\_\_

**PRICE DATA**

This section requests quarterly quantity and value data, f.o.b. your U.S. point of shipment, for your commercial shipments to unrelated U.S. customers since 2005 of the following products produced by your firm.

**Product 1.-- Pharmaceutical-grade** glycine - A white, odorless, crystalline powder with a sweet taste, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), and with no more than 70 ppm chloride, no more than 65 ppm sulfate, and no more than 10 ppm heavy metals.

**Product 2.-- USP-grade** glycine - A white, odorless, crystalline powder with a sweet taste, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), and with no more than 70 ppm chloride, no more than 65 ppm sulfate, no more than 20 ppm heavy metals, and not otherwise qualifying as pharmaceutical-grade glycine.

**Product 3.-- Technical-grade** glycine - A white, off-white, or slightly yellow crystalline powder, having an assay (glycine content) of 98.5 percent to 101.5 percent (dry basis), with no more than 200 ppm sulfates, and not otherwise qualifying as USP-grade glycine.

Note.—The pricing product data should reflect the end use for which the glycine in question is sold. The purity requirements listed for each pricing product reflect minimum purity requirements for end users in those markets. Any glycine that could be sold into a higher purity end use but is not should be recorded as a sale to the market into which it is sold. For example, if a producer produces glycine meeting the specifications for use in deodorant applications (USP grade) but sells that product for metal complexing (technical grade), that sale should be recorded as a technical grade sale.

**Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include U.S.-inland transportation costs. Total dollar values should reflect the *final net* amount paid to you (i.e., should be net of all deductions for discounts or rebates). See instruction booklet.**

**PART IV.--PRICING AND MARKET FACTORS--Continued**

IV-2. **Pricing data.**--Report below the quarterly price data<sup>1</sup> for pricing products<sup>2</sup> produced and sold by your firm.

<b>(Quantity in pounds, value in dollars)</b>						
<b>Period of shipment</b>	<b>Product 1</b>		<b>Product 2</b>		<b>Product 3</b>	
	<b>Quantity</b>	<b>Value</b>	<b>Quantity</b>	<b>Value</b>	<b>Quantity</b>	<b>Value</b>
<b>2005:</b>						
January-March						
April-June						
July-September						
October-December						
<b>2006:</b>						
January-March						
April-June						
July-September						
October-December						
<b>2007:</b>						
January-March						
April-June						
July-September						
October-December						
<b>2008:</b>						
January-March						
April-June						
July-September						
October-December						
<b>2009:</b>						
January-March						
April-June						
July-September						
October-December						
<b>2010:</b>						
January-March						
April-June						
July-September						
October-December						

<sup>1</sup> Net values (*i.e.*, gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your U.S. point of shipment.

<sup>2</sup> Pricing product definitions are provided on the first page of Part IV.

**Note.**--If your product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your product:

Product 1: \_\_\_\_\_

Product 2: \_\_\_\_\_

Product 3: \_\_\_\_\_

**PART IV.--PRICING AND MARKET FACTORS--Continued**

IV-3. **Price setting.**-- How does your firm determine the prices that it charges for sales of glycine (*check all that apply*)? If your firm issues price lists, please include a copy of a recent price list with your submission. If your price list is large, please only submit some sample pages.

- Transaction by transaction
- Contracts
- Set price lists
- Other--Please describe: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

IV-4. **Discount policy.**-- Please indicate and describe your firm's discount policies (*check all that apply*).

- Quantity discounts
- Annual total volume discounts
- No discounts
- Other--Please describe: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

IV-5. **Pricing terms for glycine.**--

- (a) What are your firm's typical sales terms for its U.S.-produced glycine (*e.g.*, 2/10 net 30 days)? \_\_\_\_\_.
- (b) On what basis are your prices of domestic glycine usually quoted? (check one)  
 F.o.b.--Please specify point: \_\_\_\_\_  Delivered

IV-6. **Contract versus spot.**--Approximately what share of your firm's sales of its U.S.-produced glycine in 2010 were on a (1) long-term contract basis (multiple deliveries for more than 12 months), (2) short-term contract basis (multiple deliveries up to and including 12 months), and (3) spot sales basis (for a single delivery)?

<u>Type of sale</u>	<u>Share of sales (percent)</u>
Long-term contracts	_____
Short-term contracts	_____
Spot sales	_____

**PART IV.--PRICING AND MARKET FACTORS--Continued**

IV-7. **Long-term contract provisions.**--If you sell on a long-term contract basis, please answer the following questions with respect to provisions of a typical long-term contract.

- (a) What is the average duration of a contract? \_\_\_\_\_
- (b) Can prices be renegotiated during the contract period?     Yes     No
- (c) Does the contract fix quantity, price, or both?     Quantity     Price     Both
- (d) Does the contract have a meet or release provision?     Yes     No

IV-8. **Short-term contract provisions.**--If you sell on a short-term contract basis, please answer the following questions with respect to provisions of a typical short-term contract.

- (a) What is the average duration of a contract? \_\_\_\_\_
- (b) Can prices be renegotiated during the contract period?     Yes     No
- (c) Does the contract fix quantity, price, or both?     Quantity     Price     Both
- (d) Does the contract have a meet or release provision?     Yes     No

IV-9. **Lead times.**--What is the average lead time between a customer's order and the date of delivery for your firm's sales of your U.S.-produced glycine?

<u>Source</u>	<u>Share of sales in 2010</u>	<u>Lead time</u>
From inventory	_____	_____
Produced to order	_____	_____
<b>Total</b>	<b>100 %</b>	

IV-10. **Shipping information.**--

- (a) What is the approximate percentage of the total delivered cost of glycine that is accounted for by U.S. inland transportation costs? \_\_\_\_\_ percent.
- (b) Who generally arranges the transportation to your customers' locations? (check one)  
 your firm or     purchaser
- (c) What proportion of your sales are delivered within 100 miles of your production facility? \_\_\_\_\_ percent. Within 101 to 1,000 miles? \_\_\_\_\_ percent. Over 1,000 miles? \_\_\_\_\_ percent.

**PART IV.--PRICING AND MARKET FACTORS--Continued**

IV-11. **Geographical shipments.**-- What is the geographic market area in the United States served by your firm's glycine? (check all that apply)

Geographic area	√ if applicable
<b>Northeast.</b> --CT, ME, MA, NH, NJ, NY, PA, RI, and VT.	<input type="checkbox"/>
<b>Midwest.</b> --IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	<input type="checkbox"/>
<b>Southeast.</b> --AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	<input type="checkbox"/>
<b>Central Southwest.</b> --AR, LA, OK, and TX.	<input type="checkbox"/>
<b>Mountains.</b> --AZ, CO, ID, MT, NV, NM, UT, and WY.	<input type="checkbox"/>
<b>Pacific Coast.</b> --CA, OR, and WA.	<input type="checkbox"/>
<b>Other.</b> --All other markets in the United States not previously listed, including AK, HI, PR, VI, among others.	<input type="checkbox"/>

IV-12. **Changes in end uses.**--Have there been any changes in the end uses of glycine since 2005?

No             Yes--Please describe.

---



---

IV-13. **Anticipated changes in end uses.**--Do you anticipate any changes in terms of the end uses of glycine in the future?

No             Yes--Please describe and identify the time period

---



---

IV-14. **Pharmaceutical grade glycine.**—Please describe and comment on the market for pharmaceutical grade glycine. How is it different from the market for USP grade glycine? What are the barriers to entry into this market? What is the role of government regulation in setting production standards?

---



---



---

**PART IV.--PRICING AND MARKET FACTORS--Continued**

IV-15 **Substitutes.**—Are there any nonsubject products that may be substituted for glycine?

No       Yes—Please fill in the following table.

Substitute product	Description of applications and end uses in which this substitute can be used	Have changes in the prices of this substitute affected the price of glycine since January 1, 2005? Please explain.	
1.		<input type="checkbox"/> No <input type="checkbox"/> Yes	<hr/> <hr/> <hr/>
2.		<input type="checkbox"/> No <input type="checkbox"/> Yes	<hr/> <hr/> <hr/>
3.		<input type="checkbox"/> No <input type="checkbox"/> Yes	<hr/> <hr/> <hr/>

IV-16. **Changes in substitutes.**--Have there been any changes in the number or types of products that can be substituted for glycine since 2005?

No       Yes--Please explain.

---

---

---

IV-17. **Anticipated changes in substitutes.**--Do you anticipate any changes in terms of the substitutability of other products for glycine in the future?

No       Yes--Please describe.

---

---

---

**PART IV.--PRICING AND MARKET FACTORS--Continued**

**IV-18. Raw materials.—**

- (a) To what extent have changes in the prices of raw materials affected your firm's selling prices for glycine since 2005?

---

---

- (b) Do you anticipated changes in your raw material costs in the foreseeable future?

No             Yes--Please explain.

---

---

- IV-19. **Changes in factors affecting supply.**--Have any changes occurred in any other factors affecting supply (e.g., changes in availability or prices of energy or labor; transportation conditions; production capacity and/or methods of production; technology; export markets; or alternative production opportunities) that affected the availability of U.S.-produced glycine in the U.S. market since 2005?

No             Yes--Please note the time period(s) of any such changes, the factors(s) involved, and the impact such changes had on your shipment volumes and prices.

---

---

---

**IV-20. Availability of supply (U.S.-produced).--**

- (a) Do you anticipate any changes in terms of the availability of U.S.-produced glycine in the U.S. market in the future?

Increase             No change             Decrease

- (b) If you anticipate changes in supply, please explain.

---

---

---

**PART IV.--PRICING AND MARKET FACTORS--Continued**

IV-21. **Availability of supply (nonsubject).**--Has the availability of NONSUBJECT glycine (*i.e.*, glycine imported from countries other than China) changed since 2005?

No             Yes--Please explain.

---

---

---

IV-22. **Export constraints.**--Can your firm shift its sales of glycine between the U.S. market and alternative country markets?

No             Yes

Please describe any contracts, other sales arrangements, or other constraints that would prevent or retard your firm from shifting glycine between the U.S. and alternative country markets within a 12-month period.

---

---

---

IV-23. **Product changes.**--Have there been any significant changes in the product range, product mix, or marketing of glycine since 2005?

No             Yes--Please describe and quantify if possible for each grade of glycine for which you are answering "Yes."

---

---

---

IV-24. **Anticipated product changes.**--Do you anticipate any changes in terms of the product range, product mix, or marketing of glycine in the future?

No             Yes--Please identify, including the time period.

---

---



**PART IV.--PRICING AND MARKET FACTORS--Continued**

**IV-25. Demand trends.--**

(a) How has the demand within the United States for glycine changed since January 1, 2005? What principal factors affect changes in demand?

Increased       No Change       Decreased       Fluctuated

---

---

---

(b) How has the demand outside the United States (if known) for glycine changed since January 1, 2005? What principal factors affect changes in demand?

Increased       No Change       Decreased       Fluctuated

---

---

**IV-26. Anticipated demand trends.--**

(a) How do you anticipate demand will change within the United States for glycine in the future? What principal factors will affect these changes in demand?

Increase       No Change       Decrease       Fluctuate

---

---

---

(b) How do you anticipate demand will change outside the United States for glycine in the future? What principal factors will affect these changes in demand?

Increase       No Change       Decrease       Fluctuate

---

---

---

**PART IV.--PRICING AND MARKET FACTORS--Continued**

**IV-27. Conditions of competition.--**

(a) Is the glycine market subject to business cycles or conditions of competition other than the changes in the overall economy?

No  Yes--Please explain and estimate the duration of any such cycle.

---

---

(b) Have the business cycles or conditions of competition for glycine changed since 2005?

No  Yes--Please explain any such changes.

---

---

**IV-28. Supply constraints.--Has your firm refused, declined, or been unable to supply glycine since January 1, 2005? (Examples include placing customers on allocation or "controlled order entry," declining to accept new customers or renew existing customers, delivering less than the quantity promised, unable to meet timely shipment commitments, etc.).**

No  Yes-- Please note and document the time period(s) (i.e., month and year), the customer involved, the amount and type of product involved; and the reason for the allocation.

---

---

---

---

**IV-29. Price comparisons.—How do the market prices of glycine in the U.S. compare with non-U.S. markets, if known? Provide specific information as to time periods and regions for any price comparisons.**

U.S. market prices are higher  Market price is the same  U.S. market prices are lower

---

---

---



